ReviewDrugs2008
Mometasone furoate: a review of its intranasal use in allergic rhinitis.
Review in Drugs, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05301647 (Mometasone Furoate Nasal Spray in Italian Children With Seasonal Allergic Rhinitis), which is not on this map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Mometasone Furoate Nasal Spray in Italian Children With Seasonal Allergic Rhinitis: a Comprehensive Assessment
Who cites it
6 citing papers in PubMed, 21 citations in OpenAlex.
- Mometasone furoate in the treatment of mild, moderate, or severe persistent allergic rhinitis: a non-inferiority study (PUMA).Brazilian journal of otorhinolaryngologyTrial
- Safety Profile of Intranasal Corticosteroids in Allergic Rhinitis: A Comprehensive Review.Biomedicines · 2026Review
- Advances in the management of allergic rhinitis: clinical relevance of the mometasone furoate-olopatadine association and the challenge of patient self-diagnosis and self-treatment.Drugs in context · 2026Review
- Efficacy and Safety Evaluation of Mometasone Furoate in Treating Ocular Inflammation.Pharmaceutics · 2023Article
- The pH Dependence of Niclosamide Solubility, Dissolution, and Morphology: Motivation for Potentially Universal Mucin-Penetrating Nasal and Throat Sprays for COVID19, its Variants and other Viral Infections.Pharmaceutical research · 2022Article
- Mometasone furoate nasal spray: a systematic review.Multidisciplinary respiratory medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mometasone furoate (Nasonex) is a high-potency intranasal corticosteroid available for the treatment and/or prophylaxis of the nasal symptoms of seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR). In the EU, it is approved for use in patients aged > or =6 years and, in the US, it is approved as a treatment in patients aged > or =2 years and as prophylaxis in those > or =12 years of age.Extensive experience in both clinical trials and the clinical practice setting has firmly established the efficacy and good tolerability profile of intranasal mometasone furoate in children and adults with PAR or SAR. Thus, intranasal mometasone furoate is a useful first-line option for the treatment and prophylactic management of these conditions, including in children as young as 2 years of age in some countries and 6 years of age in others.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.